Xiaokun Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaokun Li has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
- Chao Jiang
Wenzhou Medical University
9 shared publications - Guang Liang
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
8 shared publications Yi Wang
Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, PR China; Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
5 shared publicationsDezhong Wang
College of Life and Environmental Science, Wenzhou University, Wenzhou, 325035 Zhejiang, China
4 shared publicationsHaiyan Li
Engineering Research Center of Bioreactor and Pharmaceutical Development Ministry of Education, Jilin Agricultural University, Changchun, 130118, Jilin, China
4 shared publicationsHuanhuan Yang
School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035 Zhejiang, China
4 shared publications
Latest Publications
- Open Access
- 29 July 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-4
Author Correction: Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2)
- 29 July 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-4
Open AccessAuthor Correction: Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2)
- 6 December 2019
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 8 (7) , 1359-1370
Silver crosslinked injectable bFGF-eluting supramolecular hydrogels speed up infected wound healing
Topical wound dressings with various silver compositions that exhibit effective bacterial inhibition properties are often used to treat infected wounds. However, a silver dressing with no bioactive functionality will typically delay subsequent wound repair processes. Therefore, development of a simple wound dressing containing silver and loaded with a bioactive drug is a very attractive solution. Herein, we developed a silver crosslinked injectable chitosan–silver hydrogel as a silver immobilization matrix, loaded with basic fibroblast growth factor (bFGF) as its cargo (namely, bFGF@CS–Ag) for treatment of both acute and infected wounds. The in vivo results showed that bFGF@CS–Ag significantly enhanced infectious wound regeneration compared to that of acute wounds. Further investigation demonstrated that the improved wound repair by bFGF@CS–Ag was ascribed to the effectiveness of bacterial inhibition, the promotion of granulation formation, collagen deposition, neovascularization and re-epithelization, and to the reduction of the inflammatory response through promotion of M2 macrophage polarization. These results proved that the immobilization of silver in the hydrogel not only reduced the side effects of silver on the bioactivity of bFGF but also allowed elution of bFGF in a controlled release manner. Thus, this novel system has promising therapeutic potential for topical treatment of wounds.
- 6 December 2019
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 8 (7) , 1359-1370
Silver crosslinked injectable bFGF-eluting supramolecular hydrogels speed up infected wound healing
Topical wound dressings with various silver compositions that exhibit effective bacterial inhibition properties are often used to treat infected wounds. However, a silver dressing with no bioactive functionality will typically delay subsequent wound repair processes. Therefore, development of a simple wound dressing containing silver and loaded with a bioactive drug is a very attractive solution. Herein, we developed a silver crosslinked injectable chitosan–silver hydrogel as a silver immobilization matrix, loaded with basic fibroblast growth factor (bFGF) as its cargo (namely, bFGF@CS–Ag) for treatment of both acute and infected wounds. The in vivo results showed that bFGF@CS–Ag significantly enhanced infectious wound regeneration compared to that of acute wounds. Further investigation demonstrated that the improved wound repair by bFGF@CS–Ag was ascribed to the effectiveness of bacterial inhibition, the promotion of granulation formation, collagen deposition, neovascularization and re-epithelization, and to the reduction of the inflammatory response through promotion of M2 macrophage polarization. These results proved that the immobilization of silver in the hydrogel not only reduced the side effects of silver on the bioactivity of bFGF but also allowed elution of bFGF in a controlled release manner. Thus, this novel system has promising therapeutic potential for topical treatment of wounds.
- 26 September 2019
- Published by Wiley in Biotechnology Journal
- Vol. 15 (2) , e1900203
Structure‐Based Site‐Specific PEGylation of Fibroblast Growth Factor 2 Facilitates Rational Selection of Conjugate Sites
Polyethylene glycol modification (PEGylation) can enhance the pharmacokinetic properties of therapeutic proteins by the attachment of polyethylene glycol (PEG) to the surface of a protein to shield the protein surface from proteolytic degradation and limit aggregation. However, current PEGylation strategies often reduce biological activity, potentially as a result of steric hindrance of PEG. Overall, there are no structure‐based guidelines for selection of conjugate sites that retain optimal biological activity with improved pharmacokinetic properties. In this study, site‐specific PEGylation based on the FGF2‐FGFR1‐heparin complex structure is performed. The effects of the conjugate sites on protein function are investigated by measuring the receptor/heparin binding affinities of the modified proteins and performing assays to measure cell‐based bio‐activity and in vivo stability. Comprehensive analysis of these data demonstrates that PEGylation of FGF2 that avoids the binding sites for fibroblast growth factor receptor 1 (FGFR1) and heparin provides optimal pharmacokinetic enhancement with minimal losses to biological activity. Animal experiments demonstrate that PEGylated FGF2 exhibits greater efficacy in protecting against traumatic brain injury‐induced brain damage and neurological functions than the non‐modified FGF2. This rational structure‐based PEGylation strategy for protein modification is expected to have a major impact in the area of protein‐based therapeutics.
- 26 September 2019
- Published by Wiley in Biotechnology Journal
- Vol. 15 (2) , e1900203
Structure‐Based Site‐Specific PEGylation of Fibroblast Growth Factor 2 Facilitates Rational Selection of Conjugate Sites
Polyethylene glycol modification (PEGylation) can enhance the pharmacokinetic properties of therapeutic proteins by the attachment of polyethylene glycol (PEG) to the surface of a protein to shield the protein surface from proteolytic degradation and limit aggregation. However, current PEGylation strategies often reduce biological activity, potentially as a result of steric hindrance of PEG. Overall, there are no structure‐based guidelines for selection of conjugate sites that retain optimal biological activity with improved pharmacokinetic properties. In this study, site‐specific PEGylation based on the FGF2‐FGFR1‐heparin complex structure is performed. The effects of the conjugate sites on protein function are investigated by measuring the receptor/heparin binding affinities of the modified proteins and performing assays to measure cell‐based bio‐activity and in vivo stability. Comprehensive analysis of these data demonstrates that PEGylation of FGF2 that avoids the binding sites for fibroblast growth factor receptor 1 (FGFR1) and heparin provides optimal pharmacokinetic enhancement with minimal losses to biological activity. Animal experiments demonstrate that PEGylated FGF2 exhibits greater efficacy in protecting against traumatic brain injury‐induced brain damage and neurological functions than the non‐modified FGF2. This rational structure‐based PEGylation strategy for protein modification is expected to have a major impact in the area of protein‐based therapeutics.
- 1 January 2019
- Published by Elsevier in Molecular Immunology
- Vol. 105, 1-8
Induction of immune responses by a novel recombinant fusion protein of enterovirus A71 in BALB/c mice
- 1 January 2019
- Published by Elsevier in Molecular Immunology
- Vol. 105, 1-8
Induction of immune responses by a novel recombinant fusion protein of enterovirus A71 in BALB/c mice
- 1 December 2018
- Published by Elsevier in Protein Expression and Purification
- Vol. 152, 114-121
Highly efficient production of functional recombinant human fibroblast growth factor 22 in E. coli and its protective effects on H2O2-lesioned L02 cells
- 1 December 2018
- Published by Elsevier in Protein Expression and Purification
- Vol. 152, 114-121
Highly efficient production of functional recombinant human fibroblast growth factor 22 in E. coli and its protective effects on H2O2-lesioned L02 cells
- Open Access
- 28 March 2018
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 15 (6) , 4866-4874
Oral immunization with rotavirus VP7‑CTB fusion expressed in transgenic Arabidopsis�thaliana induces antigen‑specific IgA and IgG and passive protection in mice
Human rotavirus (HRV) is the primary cause of severe gastroenteritis in children. However, there is currently no protective virus for rotavirus available. In the present study, an HRVVP7‑cholera toxin B subunit (CTB) fusion protein was expressed in Arabidopsis thaliana. To determine the adjuvant effect of HRVVP7‑CTB, HRVVP7 without CTB was expressed in the same manner. HRVVP7‑CTB accounted for 0.39% of the total soluble protein (TSP) in the transgenic seeds and 52.65 µg/g of HRVVP7 protein was expressed in these seeds. Mice were immunized with TSP from the transformed seeds and produced serum immunoglobulin G (IgG) and mucosal IgA specifically directed against HRVVP7. Antibody titers were highest in mice orally immunized with the plant‑expressed HRVVP7‑CTB protein, whereas HRVVP7‑CTB‑specific IgG neutralized the rotavirus. Suckling pups born from dams immunized with the HRVVP7‑CTB fusion protein were protected against challenge with virulent rotavirus. The results of the present study suggest that the HRVVP7‑CTB fusion protein produced in A. thaliana may be a rotaviral‑specific candidate subunit vaccine.
- 28 March 2018
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 15 (6) , 4866-4874
Open AccessOral immunization with rotavirus VP7‑CTB fusion expressed in transgenic Arabidopsis�thaliana induces antigen‑specific IgA and IgG and passive protection in mice
Human rotavirus (HRV) is the primary cause of severe gastroenteritis in children. However, there is currently no protective virus for rotavirus available. In the present study, an HRVVP7‑cholera toxin B subunit (CTB) fusion protein was expressed in Arabidopsis thaliana. To determine the adjuvant effect of HRVVP7‑CTB, HRVVP7 without CTB was expressed in the same manner. HRVVP7‑CTB accounted for 0.39% of the total soluble protein (TSP) in the transgenic seeds and 52.65 µg/g of HRVVP7 protein was expressed in these seeds. Mice were immunized with TSP from the transformed seeds and produced serum immunoglobulin G (IgG) and mucosal IgA specifically directed against HRVVP7. Antibody titers were highest in mice orally immunized with the plant‑expressed HRVVP7‑CTB protein, whereas HRVVP7‑CTB‑specific IgG neutralized the rotavirus. Suckling pups born from dams immunized with the HRVVP7‑CTB fusion protein were protected against challenge with virulent rotavirus. The results of the present study suggest that the HRVVP7‑CTB fusion protein produced in A. thaliana may be a rotaviral‑specific candidate subunit vaccine.
- 8 November 2017
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 338, 43-53
An anti-inflammatory chalcone derivative prevents heart and kidney from hyperlipidemia-induced injuries by attenuating inflammation
- 8 November 2017
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 338, 43-53
An anti-inflammatory chalcone derivative prevents heart and kidney from hyperlipidemia-induced injuries by attenuating inflammation
- 1 October 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 139, 726-740
Discovery of new MD2-targeted anti-inflammatory compounds for the treatment of sepsis and acute lung injury
- 1 October 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 139, 726-740
Discovery of new MD2-targeted anti-inflammatory compounds for the treatment of sepsis and acute lung injury
- Open Access
- 4 July 2017
- Published by Springer Nature in BMC Biotechnology
- Vol. 17 (1) , 1-11
Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice
Fibroblast growth factor 21 (FGF21) is an endocrine-acting hormone that has the potential to treat diabetic nephropathy. However, development of FGF21 into a therapeutic has been hindered due to its low intrinsic bio-stability. In our previous study, we have developed a recombinant human FGF21 (rhFGF21) variant by site-directed mutagenesis and solid-phase PEGylation, which retained its biological function. The aim of this study is to elucidate whether the therapeutic effect of PEGylated rhFGF21 (PEG-rhFGF21) on diabetic nephropathy in DIO (diet induced obesity) mice is more significant than rhFGF21 in vivo. After administration with rhFGF21 and PEG-rhFGF21 for 2 months, biochemical data and histological examination showed that PEG-rhFGF21 significantly lowered lipid levels in the kidney, decreased urine albumin/creatinine ratio (ACR) and improved mesangial expansion, demonstrating that PEG-rhFGF21 was more efficacious in ameliorating functional and morphological abnormalities induced by diabetic nephropathy in db/db and DIO mice. Our findings suggest that PEG-rhFGF21 treatment is more effective in treating diabetic nephropathy than rhFGF21, through enhancements of systemic metabolic alterations and anti-inflammatory mechanisms. These findings help provide a theoretical basis to develop more long-acting and efficacious protein drugs for diabetic nephropathy.
- 4 July 2017
- Published by Springer Nature in BMC Biotechnology
- Vol. 17 (1) , 1-11
Open AccessPotent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice
Fibroblast growth factor 21 (FGF21) is an endocrine-acting hormone that has the potential to treat diabetic nephropathy. However, development of FGF21 into a therapeutic has been hindered due to its low intrinsic bio-stability. In our previous study, we have developed a recombinant human FGF21 (rhFGF21) variant by site-directed mutagenesis and solid-phase PEGylation, which retained its biological function. The aim of this study is to elucidate whether the therapeutic effect of PEGylated rhFGF21 (PEG-rhFGF21) on diabetic nephropathy in DIO (diet induced obesity) mice is more significant than rhFGF21 in vivo. After administration with rhFGF21 and PEG-rhFGF21 for 2 months, biochemical data and histological examination showed that PEG-rhFGF21 significantly lowered lipid levels in the kidney, decreased urine albumin/creatinine ratio (ACR) and improved mesangial expansion, demonstrating that PEG-rhFGF21 was more efficacious in ameliorating functional and morphological abnormalities induced by diabetic nephropathy in db/db and DIO mice. Our findings suggest that PEG-rhFGF21 treatment is more effective in treating diabetic nephropathy than rhFGF21, through enhancements of systemic metabolic alterations and anti-inflammatory mechanisms. These findings help provide a theoretical basis to develop more long-acting and efficacious protein drugs for diabetic nephropathy.
- Open Access
- 1 July 2017
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 33 (7) , 321-326
Rapamycin‐ameliorated diabetic symptoms involved in increasing adiponectin expression in diabetic mice on a high‐fat diet
Diabetes mellitus (DM) is one of the three most significant health problems worldwide. Previous studies proposed that insulin deficiency and (or) insulin resistance are the pathological basis of DM. β-cell dysfunction also inhibits the regulation of insulin [ [1] , [2] ]. The identification of a new drug that can counter insulin resistance or islet cell function and also prevent diabetic complications would be highly beneficial.
- 1 July 2017
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 33 (7) , 321-326
Open AccessRapamycin‐ameliorated diabetic symptoms involved in increasing adiponectin expression in diabetic mice on a high‐fat diet
Diabetes mellitus (DM) is one of the three most significant health problems worldwide. Previous studies proposed that insulin deficiency and (or) insulin resistance are the pathological basis of DM. β-cell dysfunction also inhibits the regulation of insulin [ [1] , [2] ]. The identification of a new drug that can counter insulin resistance or islet cell function and also prevent diabetic complications would be highly beneficial.